Autopsy report · NCT04480736

A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants

“portfolio reprioritization”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Janssen Research & Development, LLC

Sponsor type

Industry

Conditions

Healthy

Interventions

Placebo; JNJ-64281802 High dose; JNJ-64281802 Medium dose; JNJ-64281802 Low dose; JNJ-64281802 Dosing Regimen X; JNJ-64281802 Dosing Regimen Y

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
  “Portfolio re-prioritization” (73% match in meaning)
• Safety Study of SEA-CD40 in Cancer Patients
  “Study closed due to portfolio prioritization” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.